BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7521360)

  • 1. The interaction of immunosuppressive compounds in tandem stimulated peripheral human lymphocytes.
    Weaver JL; Pine PS; Aszalos A
    Immunopharmacol Immunotoxicol; 1994 May; 16(2):179-90. PubMed ID: 7521360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation.
    Bierer BE; Schreiber SL; Burakoff SJ
    Eur J Immunol; 1991 Feb; 21(2):439-45. PubMed ID: 1705513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
    Dumont FJ; Kastner C; Iacovone F; Fischer PA
    J Pharmacol Exp Ther; 1994 Jan; 268(1):32-41. PubMed ID: 7507994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of T and B lymphocyte proliferation by rapamycin.
    Kay JE; Kromwel L; Doe SE; Denyer M
    Immunology; 1991 Apr; 72(4):544-9. PubMed ID: 1709916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes.
    Weaver JL; Pine PS; Aszalos A
    Immunopharmacol Immunotoxicol; 1991; 13(4):563-76. PubMed ID: 1723084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A.
    Sigal NH; Lin CS; Siekierka JJ
    Transplant Proc; 1991 Apr; 23(2 Suppl 2):1-5. PubMed ID: 1712132
    [No Abstract]   [Full Text] [Related]  

  • 7. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.
    Dumont FJ; Melino MR; Staruch MJ; Koprak SL; Fischer PA; Sigal NH
    J Immunol; 1990 Feb; 144(4):1418-24. PubMed ID: 1689353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.
    Dumont FJ; Staruch MJ; Koprak SL; Melino MR; Sigal NH
    J Immunol; 1990 Jan; 144(1):251-8. PubMed ID: 1688572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
    Hess DA; Bird IA; Almawi WY; Rieder MJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of immunosuppressive drugs leaves specific "fingerprint" on gene expression in vitro.
    Rumberger B; Kreutz C; Nickel C; Klein M; Lagoutte S; Teschner S; Timmer J; Gerke P; Walz G; Donauer J
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):283-92. PubMed ID: 19235537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
    Thomson AW; Propper DJ; Woo J; Whiting PH; Milton JI; Macleod AM
    Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):355-69. PubMed ID: 7693791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts.
    Akselband Y; Harding MW; Nelson PA
    Transplant Proc; 1991 Dec; 23(6):2833-6. PubMed ID: 1721292
    [No Abstract]   [Full Text] [Related]  

  • 13. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
    Hoogduijn MJ; Crop MJ; Korevaar SS; Peeters AM; Eijken M; Maat LP; Balk AH; Weimar W; Baan CC
    Transplantation; 2008 Nov; 86(9):1283-91. PubMed ID: 19005411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506.
    Nakajima H; Oka T
    Transplant Proc; 1996 Apr; 28(2):1052-5. PubMed ID: 8623224
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
    Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
    Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.
    Zeevi A; Woan M; Yao GZ; Venkataramanan R; Todo S; Starzl TE; Duquesnoy RJ
    Transplant Proc; 1991 Dec; 23(6):2928-30. PubMed ID: 1721315
    [No Abstract]   [Full Text] [Related]  

  • 18. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells.
    Puzik A; Schultz C; Iblher P; Müller-Steinhardt M; Härtel C
    Acta Paediatr; 2007 Oct; 96(10):1483-9. PubMed ID: 17880416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506).
    Nowaczyk M; Stephień-Sopniewska B; Korczak-Kowalska G; Mrowiec T; Górski A
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):329-32. PubMed ID: 8744655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.